Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

OBJECTIVE: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19). METHODS: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18–75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Udwadia, Zarir F., Singh, Pawan, Barkate, Hanmant, Patil, Saiprasad, Rangwala, Shabbir, Pendse, Amol, Kadam, Jatin, Wu, Wen, Caracta, Cynthia F., Tandon, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/
https://www.ncbi.nlm.nih.gov/pubmed/33212256
http://dx.doi.org/10.1016/j.ijid.2020.11.142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/
https://www.ncbi.nlm.nih.gov/pubmed/33212256
http://dx.doi.org/10.1016/j.ijid.2020.11.142

Ejemplares similares